Novartis is a global healthcare company based in Basel, Switzerland, whose mission is to use science-based innovation to address some of society’s most challenging healthcare issues. The Novartis Group operates primarily through three divisions that each have a global scale. These divisions are Novartis Pharma, Novartis Oncology and Sandoz.
The Novartis Pharma portfolio addresses a wide range of therapeutic areas, including cardiovascular-metabolic, ophthalmology, respiratory, neuroscience, immunology, and dermatology. Novartis Oncology is a leader in driving the practice of precision oncology treatment.
Sandoz is a global leader in generic pharmaceuticals and biosimilars, pioneering novel approaches to help people around the world access high-quality medicines. Sandoz has a portfolio of more than 1,000 products covering all major therapeutic areas.
Novartis has been committed to Turkey for more than 60 years. Today, the Novartis Group is locally manufacturing its key products for both Turkey and export markets. The Group employs more than 2,300 qualified people and has assumed the leading role in the sector with its understanding of creating a people-oriented company culture and the best working place for its employees.
In 2018, Novartis Turkey’s total export was USD 122 million. Over the last decade, its exports have exceeded USD 1.5 billion in total.
The Novartis Group is also the leading pharma company in clinical research. Since 2009, Novartis Turkey has invested USD 209 million in clinical trials in Turkey, helping make Turkish doctors globally more competitive in research.
The long-term goal of Novartis Turkey is to continue growing with Turkey and to assume a pioneering role in further advancing the local pharmaceutical industry with more investment, more R&D, and more output.